Abstract #0718

Hyperpolarized [1-13C]Pyruvate MRSI at 48 hrs post anti-VEGF Treatment Predicts Response in C6 Glioma Implanted Rats

Keshav Datta^1,2, Mette Hauge Lauritzen¹, Milton Merchant³, Taichang Yang³, Shie-Chau Liu¹, Ronald Watkins¹, Ralph Hurd¹, Lawrence Recht³, and Daniel Mark Spielman^1,2

¹Radiology, Stanford University, Stanford, CA, United States, ²Electrical Engineering, Stanford University, Stanford, CA, United States, ³Neurology, Stanford University, Stanford, CA, United States

Using a bolus injection of hyperpolarized [1-¹³C]Pyruvate, we show that measurement of the resulting ¹³C-Lactate to ¹³C-Bicarbonate ratio 48-hours post-treatment with anti-angiogenic drug Bevacizumab (Bev20) predicts survival in a C6-Glioma rat model. A positive correlation of Lac/Bic with tumor growth rate further supports our hypothesis that the effect of the drug in survivors is to reverse the tumor Warburg metabolic phenotype necessary to support rapid proliferation.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.